The National Academies Press

Currently Skimming:

APPENDIX
Pages 18-20

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 18... ... Appendix Workshop Program Collaboration Between Government and Industry: Challenges and Opportunities for HIV Drug and Vaccine Development May 6, 1994 9:00 Welcome and Introduction Paul Volberding, Chief AIDS Program and Clinical Oncology, San Francisco General Hospital, and Roundtable Cochair 9:15 Importance and Value of Government-Industry Collaboration on HIV Drug and Vaccine Development Patrick Gage, Chief Operating OJ7icer, Genetics Institute, Inc. 9:30 Historical Perspectives on Government Technology Transfer Policy and the Pharmaceutical Industry Discussion Leader: Peter Barton Hutt, Partner, Covington & Burling Understanding the Legislative History of Intellectual Property Rights Involving the Pharmaceutical Industry Peter Barton Hutt, Partner, Covington & Burling Understanding the History of Fair Pricing Clauses and Their Implementation in Government Licensing of Intellectual Property Thomas Mays, Director, Office of Technology Development, National Cancer Institute 0:00 0:30 Discussion Break 18 Read the entire page →
From page 19... ... AIDS DRUG DEVELOPMENT 1 0:45 1 1:30 Discussion 1:00 2:00 19 Impediments to Collaboration on HIV Drug and Vaccine Development: Defining the Issues Discussion Leader: Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. Commentary from a Government/NIH Perspective � Bruce Chabner, Director, Division of Cancer Treatment, National Cancer Institute A View from the Pharmaceutical Industry � Stephen Carter, Senior Vice President, World Wide Clinical Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute Practical Implications of Rules Governing Intellectual Property Developed from Collaborative Relationships � Harold Edgar, Professor of Law, Columbia University School of Law Lunch Overcoming Obstacles to Collaboration and Promoting HIV Drug and Vaccine Development: Proposals for Resolution Discussion Leader: Martin Delaney, Founding Director, Project Inform Industry Perspective � David Barry, Group Director, Research, Development and Medical Affairs, The Wellcome Research Laboratories Government/NIH Perspective Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases Congressional/Legislative Response � Timothy Westmoreland, Counsel, Subcommittee on Health and the Environment, U.S. Read the entire page →
From page 20... ... Hanes Professor of Medicine, Director, Duke University Arthritis Center; and Roundtable Cochair Adjourn Read the entire page →

From page 18...

... Appendix Workshop Program Collaboration Between Government and Industry: Challenges and Opportunities for HIV Drug and Vaccine Development May 6, 1994 9:00 Welcome and Introduction Paul Volberding, Chief AIDS Program and Clinical Oncology, San Francisco General Hospital, and Roundtable Cochair 9:15 Importance and Value of Government-Industry Collaboration on HIV Drug and Vaccine Development Patrick Gage, Chief Operating OJ7icer, Genetics Institute, Inc. 9:30 Historical Perspectives on Government Technology Transfer Policy and the Pharmaceutical Industry Discussion Leader: Peter Barton Hutt, Partner, Covington & Burling Understanding the Legislative History of Intellectual Property Rights Involving the Pharmaceutical Industry Peter Barton Hutt, Partner, Covington & Burling Understanding the History of Fair Pricing Clauses and Their Implementation in Government Licensing of Intellectual Property Thomas Mays, Director, Office of Technology Development, National Cancer Institute 0:00 0:30 Discussion Break 18

Read the entire page →

From page 19...

... AIDS DRUG DEVELOPMENT 1 0:45 1 1:30 Discussion 1:00 2:00 19 Impediments to Collaboration on HIV Drug and Vaccine Development: Defining the Issues Discussion Leader: Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. Commentary from a Government/NIH Perspective � Bruce Chabner, Director, Division of Cancer Treatment, National Cancer Institute A View from the Pharmaceutical Industry � Stephen Carter, Senior Vice President, World Wide Clinical Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute Practical Implications of Rules Governing Intellectual Property Developed from Collaborative Relationships � Harold Edgar, Professor of Law, Columbia University School of Law Lunch Overcoming Obstacles to Collaboration and Promoting HIV Drug and Vaccine Development: Proposals for Resolution Discussion Leader: Martin Delaney, Founding Director, Project Inform Industry Perspective � David Barry, Group Director, Research, Development and Medical Affairs, The Wellcome Research Laboratories Government/NIH Perspective Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases Congressional/Legislative Response � Timothy Westmoreland, Counsel, Subcommittee on Health and the Environment, U.S.

Read the entire page →

From page 20...

... Hanes Professor of Medicine, Director, Duke University Arthritis Center; and Roundtable Cochair Adjourn

Read the entire page →

Key Terms

← Previous Chapter Skim

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

APPENDIX Pages 18-20

APPENDIX
Pages 18-20